On the afternoon of September 11th, Lv X♦✘iangyang, Chairman of the Youngy ≠✘→Group, visited Nanjing Regenecore Companδ™y and Thoth Institutes to gain a comprehens✔★ive understanding of the current development s‍ ♣≈tatus and future innovative directions of the t£÷✔wo organizations. Accompanied by Chief S ←ε∑cientist Xie Wei and Gene"ε ral Manager Wang Yang≈φ of Regenecore, Lv Xiangyang toured the R&®δ×;D platform of Regenecore an×☆≠d the scientific research center of Tβ∏©hoth Institutes. Wang Yang prov✘←ided a detailed introducti×α♦∑on to the company's structure, R&aπ§↑βmp;D platform, product p™↑​₽ipeline, and progress. Chief Scientist←> Xie Wei elaborated on Thot™ h Institutes' plannin<♥₹g guided by the "F≥‌our Orientations" philosophy, its innovati♠® ve mechanisms, and profound reflections on prφ‌‍esent and future scenarios.

Lv Xiangyang engaged in insightful conv♠φ♥ersations with the heads of variou&¶↔§s departments at Regenecore, acknowle₹§↓σdging the innovative spirit and scientific∞←÷ research capabilities dem€‌onstrated by both Regenecore and&  Thoth Institutes. He emphasized that the Group £γwould offer more support and guidan©§₩↑ce in the future to accelerat™ ​e the development of projects σ↕related to antibody drugs and human health enha∞εncement. It aims to facili•₩α≤tate rapid project transformation throug↔♦h multiple channels and levels, contributing to ® "ΩChina's biomedicine indu↕¥Ωstry and benefiting the br€♣oad masses of the people.